We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
OTLK Up More Than 300% in 3 Months: Here's What You Should Know
Read MoreHide Full Article
Key Takeaways
Outlook Therapeutics' shares jumped 311.8% in three months as Lytenava won FDA approval for wet AMD.
OTLK expects to launch Lytenava in the U.S. by 2026-end, making the rollout a potential stock catalyst.
OTLK expects Lytenava sales in Europe could improve sequentially as unit sales are likely to recover.
Shares of Outlook Therapeutics (OTLK - Free Report) have witnessed a significant surge over the past three months, primarily driven by growing investor optimism related to the company’s sole product, Lytenava, which is approved for the treatment of patients with wet age-related macular degeneration (wet AMD).
OTLK’s Price Performance
Shares of Outlook Therapeutics have skyrocketed 311.8% in the past three months compared with the industry’s increase of 6.9%.
Image Source: Zacks Investment Research
Last month, the FDA approved Lytenava for the treatment of neovascular age-related macular degeneration (nAMD), commonly known as wet AMD. The approval, which came ahead of schedule, marked a significant milestone for the company, with the prospect of bringing the drug to the U.S. market.
In June 2026, the FDA accepted the resubmitted biologics license application (BLA) for Lytenava in wet AMD.
The approval followed the FDA’s acceptance of the resubmitted BLA, after the company resolved the issues raised in the FDA’s complete response letter in December 2025. Outlook Therapeutics expects to launch Lytenava in the United States by the end of 2026, making the upcoming commercial launch an important potential catalyst for the stock.
As Outlook Therapeutics prepares to report its third-quarter fiscal 2026 results later this week, investors are likely to focus on the company’s U.S. launch plans for Lytenava. A successful launch could improve investor confidence in Lytenava’s revenue potential and provide further upside to OTLK shares.
More on OTLK’s Lytenava Rollout in Europe
Lytenava has been commercialized across the European Union and the United Kingdom since 2024. Outlook Therapeutics commenced commercial launch of Lytenava in Germany and the United Kingdom as a treatment for wet AMD.
Over the past few quarters, Outlook Therapeutics has generated modest revenues from Lytenava sales in ex-U.S. markets. However, European product sales are likely to improve sequentially, as Lytenava is already launched in select markets and management previously noted a recovery in unit sales following an initial slowdown.
Now that Lytenava is approved by the FDA, it should hold stronger commercial momentum ahead of the planned U.S. launch.
It can be inferred that the company will be more focused on the U.S. commercial rollout, inventory availability and reimbursement progress of Lytenava.
Outlook Therapeutics’ recent development with Lytenava indicates long-term growth potential.
Over the past 60 days, estimates for Harmony Biosciences’ 2026 earnings per share have risen from $3.20 to $3.62, while estimates for 2027 have increased from $3.64 to $4.07 during the same time. HRMY shares have gained 2.6% year to date.
Harmony Biosciences’ earnings missed estimates in three of the trailing four quarters and beat on the remaining occasion, delivering an average negative surprise of 13.97%.
Over the past 60 days, estimates for Repligen’s 2026 earnings per share have risen from $1.99 to $2.06, while estimates for 2027 have increased from $2.57 to $2.62 during the same time. RGEN shares failed to deliver any returns year to date.
Repligen’s earnings beat estimates in each of the trailing four quarters, with the average surprise being 16.80%.
Over the past 60 days, estimates for Liquidia’s 2026 earnings per share have risen from $2.97 to $3.02, while estimates for 2027 have increased from $4.81 to $5.31 during the same time. LQDA shares have surged 161.3% year to date.
Liquidia’s earnings beat estimates in three of the trailing four quarters, while missing the same on the remaining occasion, with the average surprise being 54.40%.
View the Zacks #1 Rank List
Image: Bigstock
OTLK Up More Than 300% in 3 Months: Here's What You Should Know
Key Takeaways
Shares of Outlook Therapeutics (OTLK - Free Report) have witnessed a significant surge over the past three months, primarily driven by growing investor optimism related to the company’s sole product, Lytenava, which is approved for the treatment of patients with wet age-related macular degeneration (wet AMD).
OTLK’s Price Performance
Shares of Outlook Therapeutics have skyrocketed 311.8% in the past three months compared with the industry’s increase of 6.9%.
Image Source: Zacks Investment Research
Last month, the FDA approved Lytenava for the treatment of neovascular age-related macular degeneration (nAMD), commonly known as wet AMD. The approval, which came ahead of schedule, marked a significant milestone for the company, with the prospect of bringing the drug to the U.S. market.
In June 2026, the FDA accepted the resubmitted biologics license application (BLA) for Lytenava in wet AMD.
The approval followed the FDA’s acceptance of the resubmitted BLA, after the company resolved the issues raised in the FDA’s complete response letter in December 2025. Outlook Therapeutics expects to launch Lytenava in the United States by the end of 2026, making the upcoming commercial launch an important potential catalyst for the stock.
As Outlook Therapeutics prepares to report its third-quarter fiscal 2026 results later this week, investors are likely to focus on the company’s U.S. launch plans for Lytenava. A successful launch could improve investor confidence in Lytenava’s revenue potential and provide further upside to OTLK shares.
More on OTLK’s Lytenava Rollout in Europe
Lytenava has been commercialized across the European Union and the United Kingdom since 2024. Outlook Therapeutics commenced commercial launch of Lytenava in Germany and the United Kingdom as a treatment for wet AMD.
Over the past few quarters, Outlook Therapeutics has generated modest revenues from Lytenava sales in ex-U.S. markets. However, European product sales are likely to improve sequentially, as Lytenava is already launched in select markets and management previously noted a recovery in unit sales following an initial slowdown.
Now that Lytenava is approved by the FDA, it should hold stronger commercial momentum ahead of the planned U.S. launch.
It can be inferred that the company will be more focused on the U.S. commercial rollout, inventory availability and reimbursement progress of Lytenava.
Outlook Therapeutics’ recent development with Lytenava indicates long-term growth potential.
Outlook Therapeutics, Inc. Price
Outlook Therapeutics, Inc. price | Outlook Therapeutics, Inc. Quote
OTLK’s Zacks Rank & Stocks to Consider
Outlook Therapeutics currently carries a Zacks Rank #3 (Hold).
Some better-ranked stocks in the biotech sector are Harmony Biosciences (HRMY - Free Report) , Repligen (RGEN - Free Report) and Liquidia Corporation (LQDA - Free Report) , each currently sporting a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Over the past 60 days, estimates for Harmony Biosciences’ 2026 earnings per share have risen from $3.20 to $3.62, while estimates for 2027 have increased from $3.64 to $4.07 during the same time. HRMY shares have gained 2.6% year to date.
Harmony Biosciences’ earnings missed estimates in three of the trailing four quarters and beat on the remaining occasion, delivering an average negative surprise of 13.97%.
Over the past 60 days, estimates for Repligen’s 2026 earnings per share have risen from $1.99 to $2.06, while estimates for 2027 have increased from $2.57 to $2.62 during the same time. RGEN shares failed to deliver any returns year to date.
Repligen’s earnings beat estimates in each of the trailing four quarters, with the average surprise being 16.80%.
Over the past 60 days, estimates for Liquidia’s 2026 earnings per share have risen from $2.97 to $3.02, while estimates for 2027 have increased from $4.81 to $5.31 during the same time. LQDA shares have surged 161.3% year to date.
Liquidia’s earnings beat estimates in three of the trailing four quarters, while missing the same on the remaining occasion, with the average surprise being 54.40%.